D
Rhythm Pharmaceuticals, Inc.
RYTM
$50.97
$0.731.45%
D
Sell
1/15/2025Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 1/15/2025 due to an increase in the solvency index and volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 1/15/2025 due to an increase in the solvency index and volatility index.
E
Sell
11/7/2024Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 11/7/2024 due to a noticeable decline in the growth index, solvency index and total return index. Debt to equity increased from 2.78 to 9.74, the quick ratio declined from 6.15 to 3.25, and earnings per share declined from -$0.5501 to -$0.7346.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 11/7/2024 due to a noticeable decline in the growth index, solvency index and total return index. Debt to equity increased from 2.78 to 9.74, the quick ratio declined from 6.15 to 3.25, and earnings per share declined from -$0.5501 to -$0.7346.
D
Sell
10/31/2024Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 10/31/2024 due to a noticeable increase in the total return index, solvency index and volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 10/31/2024 due to a noticeable increase in the total return index, solvency index and volatility index.
E
Sell
8/8/2024Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 8/8/2024 due to a decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.76 to 2.78.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 8/8/2024 due to a decline in the solvency index, growth index and valuation index. Debt to equity increased from 1.76 to 2.78.
D
Sell
3/25/2024Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 3/25/2024 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7631 to -$0.7031, total revenue increased 7.69% from $22.5M to $24.23M, and EBIT increased 6.12% from -$43.95M to -$41.27M.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 3/25/2024 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7631 to -$0.7031, total revenue increased 7.69% from $22.5M to $24.23M, and EBIT increased 6.12% from -$43.95M to -$41.27M.
E
Sell
5/31/2023Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 5/31/2023 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.53 to 6.58.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D- on 5/31/2023 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 8.53 to 6.58.
D
Sell
3/14/2023Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 03/14/2023.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 52.75% from $9.07M to $4.28M, and operating cash flow declined 21.07% from -$38.81M to -$46.99M.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 2/8/2023 due to a decline in the growth index and valuation index. Total revenue declined 52.75% from $9.07M to $4.28M, and operating cash flow declined 21.07% from -$38.81M to -$46.99M.
D
Sell
8/19/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/19/2022 due to an increase in the total return index, growth index and volatility index. Total revenue increased 505.21% from $1.5M to $9.07M, operating cash flow increased 27.64% from -$53.63M to -$38.81M, and earnings per share increased from -$1.05 to -$0.8929.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/19/2022 due to an increase in the total return index, growth index and volatility index. Total revenue increased 505.21% from $1.5M to $9.07M, operating cash flow increased 27.64% from -$53.63M to -$38.81M, and earnings per share increased from -$1.05 to -$0.8929.
D
Sell
5/4/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 5/4/2022 due to an increase in the valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/22/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from E+ on 04/22/2022.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from E+ on 04/22/2022.
E
Sell
4/20/2022Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 4/18/2022 due to an increase in the volatility index and valuation index.
D
Sell
3/30/2022Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 3/30/2022 due to a decline in the volatility index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 3/30/2022 due to a decline in the volatility index and valuation index.
D
Sell
3/4/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 3/4/2022 due to an increase in the volatility index and growth index. Total revenue increased 76.75% from $1.03M to $1.82M.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 3/4/2022 due to an increase in the volatility index and growth index. Total revenue increased 76.75% from $1.03M to $1.82M.
D
Sell
2/7/2022Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 2/7/2022 due to a decline in the volatility index and total return index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 2/7/2022 due to a decline in the volatility index and total return index.
D
Sell
1/19/2022Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 1/19/2022 due to an increase in the volatility index, total return index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 1/19/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
12/30/2021Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 12/30/2021 due to a decline in the volatility index, total return index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 12/30/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
12/13/2021Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index, total return index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 12/13/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
11/24/2021Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 11/24/2021 due to a decline in the volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 11/24/2021 due to a decline in the volatility index.
D
Sell
11/5/2021Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 11/5/2021 due to an increase in the growth index and volatility index. Total revenue increased 275.18% from $274 to $1.03M, and earnings per share increased from -$0.7048 to -$0.6987.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 11/5/2021 due to an increase in the growth index and volatility index. Total revenue increased 275.18% from $274 to $1.03M, and earnings per share increased from -$0.7048 to -$0.6987.
D
Sell
11/3/2021Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 11/3/2021 due to a decline in the total return index and volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 11/3/2021 due to a decline in the total return index and volatility index.
D
Sell
10/8/2021Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 10/8/2021 due to an increase in the volatility index and valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 10/8/2021 due to an increase in the volatility index and valuation index.
D
Sell
9/23/2021Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 9/23/2021 due to a decline in the total return index and volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 9/23/2021 due to a decline in the total return index and volatility index.
D
Sell
8/4/2020Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/4/2020 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 17.64% from -$36.1M to -$29.73M, and earnings per share increased from -$0.7756 to -$0.71.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/4/2020 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 17.64% from -$36.1M to -$29.73M, and earnings per share increased from -$0.7756 to -$0.71.
D
Sell
3/12/2019Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 3/12/2019 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 34.91 to 18.56, net income declined 44.22% from -$17.69M to -$25.51M, and total capital declined 8.67% from $269.64M to $246.26M.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to D- from D on 3/12/2019 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 34.91 to 18.56, net income declined 44.22% from -$17.69M to -$25.51M, and total capital declined 8.67% from $269.64M to $246.26M.
D
Sell
8/9/2018Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/9/2018 due to a noticeable increase in the total return index, valuation index and growth index. Earnings per share increased from -$0.6032 to -$0.52, and EBIT increased 11.65% from -$17M to -$15.02M.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D from D- on 8/9/2018 due to a noticeable increase in the total return index, valuation index and growth index. Earnings per share increased from -$0.6032 to -$0.52, and EBIT increased 11.65% from -$17M to -$15.02M.
D
Sell
6/22/2018Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E on 6/22/2018 due to an increase in the volatility index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to D- from E on 6/22/2018 due to an increase in the volatility index.
E
Sell
4/2/2018Upgraded
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to E from E- on 4/2/2018 due to an increase in the valuation index and total return index.
Rhythm Pharmaceuticals, Inc. (RYTM) was upgraded to E from E- on 4/2/2018 due to an increase in the valuation index and total return index.
E
Sell
3/13/2018Downgrade
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E- from E on 3/13/2018 due to a decline in the valuation index.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E- from E on 3/13/2018 due to a decline in the valuation index.
E
Sell
12/29/2017None
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E from U on 12/29/2017.
Rhythm Pharmaceuticals, Inc. (RYTM) was downgraded to E from U on 12/29/2017.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
